SCHEMBL1353007

SCHEMBL1353007

COc1ccc(NC(=O)c2cc(C(N)=O)ccc2OC)c(OC)c1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 4/20 0.66
NPC1 O15118 2/20 0.66
RAB9A P51151 2/20 0.66
LMNA P02545 2/20 0.66
AHR P35869 1/20 0.66
CYP1A1 P04798 1/20 0.61
CYP1A2 P05177 1/20 0.61
CYP1B1 Q16678 1/20 0.61
MAPT P10636 4/20 0.60
MEN1 O00255 4/20 0.60
KMT2A Q03164 4/20 0.60
ALDH1A1 P00352 3/20 0.60
KDM4E B2RXH2 1/20 0.56
HPGD P15428 1/20 0.56
TP53 P04637 1/20 0.56
GAA P10253 1/20 0.56
HDAC8 Q9BY41 1/20 0.55
TAS1R3 Q7RTX0 1/20 0.55
TAS1R1 Q7RTX1 1/20 0.55
TAS1R2 Q8TE23 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1353257 0.91 TP53 (0.68) SMN1; SMN2NPC1RAB9ALMNAAHR
SCHEMBL1351278 0.88 GAA (0.57) SMN1; SMN2NPC1RAB9ALMNAAHR
SCHEMBL12132771 0.86 TP53 (0.55) SMN1; SMN2NPC1RAB9ALMNAAHR
SCHEMBL1353113 0.84 RAB9A (0.64) SMN1; SMN2RAB9ALMNAAHRCYP1A2
SCHEMBL31680510 0.82 SMN1; SMN2 (0.88) SMN1; SMN2NPC1RAB9ALMNAAHR
SCHEMBL1352849 0.82 PLAU (0.69) SMN1; SMN2NPC1RAB9ACYP1A2MEN1
SCHEMBL1353058 0.81 KDM4E (0.64) SMN1; SMN2NPC1RAB9ALMNACYP1A2
SCHEMBL24711273 0.81 LMNA (0.86) SMN1; SMN2NPC1RAB9ALMNAAHR
SCHEMBL1353382 0.80 KCNMA1 (0.58) NPC1RAB9AMAPTMEN1KMT2A
SCHEMBL12134197 0.80 RAB9A (0.55) NPC1RAB9ACYP1A2MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8063046-B2 Benzamide derivative CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2011-11-22 US disclosed
US-8063046-B2 Benzamide derivative CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2011-11-22 US disclosed
US-8063046-B2 Benzamide derivative CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2011-11-22 US disclosed
EP-1698618-B1 BENZAMIDE DERIVATIVE CHUGAI PHARMACEUTICAL CO LTD (JP) 2011-05-18 EP disclosed
US-20100179326-A1 BENZAMIDE DERIVATIVE CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2010-07-15 US disclosed
US-20100179326-A1 BENZAMIDE DERIVATIVE CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2010-07-15 US disclosed
US-20100179326-A1 BENZAMIDE DERIVATIVE CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2010-07-15 US disclosed
US-7705053-B2 Benzamide derivative CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2010-04-27 US disclosed
US-7705053-B2 Benzamide derivative CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2010-04-27 US disclosed
US-7705053-B2 Benzamide derivative CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2010-04-27 US disclosed
US-20070123493-A1 Benzamide derivative CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2007-05-31 US disclosed
US-20070123493-A1 Benzamide derivative CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2007-05-31 US disclosed
US-20070123493-A1 Benzamide derivative CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2007-05-31 US disclosed
EP-1698618-A1 BENZAMIDE DERIVATIVE CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2006-09-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070123493-A1 Benzamide derivative BDKRB1, BDKRB2, NR1H2 SMN1; SMN2 3867/4885NPC1 540/4885RAB9A 2244/4885
US-20100179326-A1 BENZAMIDE DERIVATIVE NR0B2, NR1H2, CNR2 SMN1; SMN2 3723/4885NPC1 955/4885RAB9A 2884/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.